Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.…
Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 36 employees.
The shares were at 2.060 USD on 20 November 2026, down 80.4% over 52 weeks. Its 52-week range is 2.010 USD to 12.88 USD: the price is 84.0% below the high and 2.5% above the low.
Its market capitalisation is 42.45M USD.
Corbus Pharmaceuticals Holdings reports return on equity of -53.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 111.43M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 15 March 2027.